Navamedic ASA (OSL:NAVA)

Market Cap	388.50M -0.9%
Revenue (ttm)	571.24M +5.3%
Net Income	-16.20M
EPS	-0.79
Shares Out	23.98M
PE Ratio	n/a
Forward PE	76.24
Dividend	n/a
Ex-Dividend Date	n/a

Volume	21,209
Open	15.85
Previous Close	16.20
Day's Range	15.70 - 16.40
52-Week Range	15.70 - 27.90
Beta	0.22
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 14, 2026

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propionic...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 38
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2025, Navamedic ASA's revenue was 565.36 million, an increase of 6.38% compared to the previous year's 531.44 million. Losses were -23.54 million, 329.1% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 25, 2026

Data Sources Report a data error